Drug-eluting Balloon (DEB) for De-Novo Coronary Artery Disease and In-stent Restenosis: Immediate and Intermediate Term Results from a Prospective Registry

Objectives: to study the safety and short and intermediate term efficacy of drug-eluting balloon (deb) in the treatment of de-novo and in-stent restenotic coronary artery disease (cad).methods: of the total 100 patients so far enrolled in a prospective deb registry using a paclitaxel-coated balloon at our hospital, 36 patients were studied for short and intermediate term i.e. 12 months outcomes. all patients with symptomatic coronary artery disease (cad) including de-novo lesions or in-stent restenosis (isr) requiring percutaneous intervention (pci) with a deb were included. clinical follow-up was conducted at 3, 6 and 12 months. primary outcome was a composite of major adverse cardiac events (mace).results: procedural success was achieved in all (100%) patients. mean age was 53.2 ± 12 years, 61.1% presented with acute coronary syndrome (acs) and 47.2% had triple vessel cad. sixty six percent were classified as having acc/aha b-2 or c type coronary arteries including 22.2% with bifurcation lesions. deb intervention for de-novo cad was done in 77.7% patients and 22.2% for isr. all de-novo lesions required a bare- metal stent (bms) after deb dilatation. mean deb diameter was 2.73 ± 0.06 mm and mean length was 19.58 ± 0.81 mm. coronary dissections occurred in 5 patients which were successfully treated with additional stents. at 3 (n=36), 6 (n=31)and 12(n=31) months follow-up, no mace was observed in any patient.conclusion: the short and intermediate term outcomes from this prospective deb registry showed excellent results with 0% target lesion revascularization (tlr) for both de-novo and isr lesions.